196 related articles for article (PubMed ID: 33959472)
1. In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus.
Tietcheu Galani BR; Ayissi Owona VB; Guemmogne Temdie RJ; Metzger K; Atsama Amougou M; Djamen Chuisseu PD; Fondjo Kouam A; Ngounoue Djuidje M; Aliouat-Denis CM; Cocquerel L; Fewou Moundipa P
In Silico Pharmacol; 2021; 9(1):35. PubMed ID: 33959472
[TBL] [Abstract][Full Text] [Related]
2. Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus.
Bhise N; Agarwal M; Thakur N; Akshay PS; Cherian S; Lole K
Arch Virol; 2023 Apr; 168(5):147. PubMed ID: 37115342
[TBL] [Abstract][Full Text] [Related]
3. Modelling of Hepatitis E virus RNA-dependent RNA polymerase genotype 3 from a chronic patient and
Cancela F; Rendon-Marin S; Quintero-Gil C; Houston DR; Gumbis G; Panzera Y; Pérez R; Arbiza J; Mirazo S
J Biomol Struct Dyn; 2023 Feb; 41(2):705-721. PubMed ID: 34861797
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Candidates for Treating Hepatitis E Virus Infection.
Netzler NE; Enosi Tuipulotu D; Vasudevan SG; Mackenzie JM; White PA
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885901
[TBL] [Abstract][Full Text] [Related]
5. Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.
Singh SK; Upadhyay AK; Reddy MS
3 Biotech; 2021 Feb; 11(2):93. PubMed ID: 33520579
[TBL] [Abstract][Full Text] [Related]
6. High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection.
Liang Z; Shu J; He Q; Zhang F; Dai L; Wang L; Lu F; Wang L
Antiviral Res; 2022 Mar; 199():105274. PubMed ID: 35247472
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment.
Gömer A; Dinkelborg K; Klöhn M; Jagst M; Wißing MH; Frericks N; Nörenberg P; Behrendt P; Cornberg M; Wedemeyer H; Steinmann E; Maasoumy B; Todt D
JHEP Rep; 2024 Mar; 6(3):100989. PubMed ID: 38434938
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore-Model-Based Drug Repurposing for the Identification of the Potential Inhibitors Targeting the Allosteric Site in Dengue Virus NS5 RNA-Dependent RNA Polymerase.
Kumar S; Bajrai LH; Faizo AA; Khateb AM; Alkhaldy AA; Rana R; Azhar EI; Dwivedi VD
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016449
[TBL] [Abstract][Full Text] [Related]
10. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.
Udofia IA; Gbayo KO; Oloba-Whenu OA; Ogunbayo TB; Isanbor C
Netw Model Anal Health Inform Bioinform; 2021; 10(1):22. PubMed ID: 33786291
[TBL] [Abstract][Full Text] [Related]
11. Repositioning of RdRp Inhibitors Against HCV NS5B Polymerase Utilizing Structure-Based Molecular Docking.
Tarannum H; Nandi S
Comb Chem High Throughput Screen; 2022; 25(4):702-719. PubMed ID: 33475069
[TBL] [Abstract][Full Text] [Related]
12. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
13. Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An
Akinlalu AO; Chamundi A; Yakumbur DT; Afolayan FID; Duru IA; Arowosegbe MA; Enejoh OA
Sci Afr; 2021 Sep; 13():e00845. PubMed ID: 34308004
[TBL] [Abstract][Full Text] [Related]
14. An Exploration of the Inhibitory Mechanism of Rationally Screened Benzofuran-1,3,4-Oxadiazoles and-1,2,4-Triazoles as Inhibitors of NS5B RdRp Hepatitis C Virus through Pharmacoinformatic Approaches.
Irfan A; Faisal S; Ahmad S; Saif MJ; Zahoor AF; Khan SG; Javid J; Al-Hussain SA; Muhammed MT; Zaki MEA
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002085
[TBL] [Abstract][Full Text] [Related]
15. Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.
Nishiyama T; Kobayashi T; Jirintai S; Nagashima S; Primadharsini PP; Nishizawa T; Okamoto H
Antiviral Res; 2019 Oct; 170():104570. PubMed ID: 31362004
[TBL] [Abstract][Full Text] [Related]
16. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
17. In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases.
Chowdhury T; Roymahapatra G; Mandal SM
Infect Disord Drug Targets; 2021; 21(4):608-618. PubMed ID: 32718300
[TBL] [Abstract][Full Text] [Related]
18. Positive Regulation of Hepatitis E Virus Replication by MicroRNA-122.
Haldipur B; Bhukya PL; Arankalle V; Lole K
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540601
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach.
Zapata-Cardona MI; Florez-Alvarez L; Guerra-Sandoval AL; Chvatal-Medina M; Guerra-Almonacid CM; Hincapie-Garcia J; Hernandez JC; Rugeles MT; Zapata-Builes W
AIMS Microbiol; 2023; 9(1):20-40. PubMed ID: 36891537
[TBL] [Abstract][Full Text] [Related]
20. Screening of novel drugs for inhibiting hepatitis E virus replication.
Nishiyama T; Kobayashi T; Jirintai S; Kii I; Nagashima S; Prathiwi Primadharsini P; Nishizawa T; Okamoto H
J Virol Methods; 2019 Aug; 270():1-11. PubMed ID: 31004661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
